4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down Following Insider Selling
Related Articles
-
Q2 2024 EPS Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO) Lifted by HC Wainwright
Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – HC Wainwright increased their Q2 2024 EPS estimates for shares of Spero Therapeutics in a research note issued on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.25) per share for the quarter, up from their prior estimate of ($0.41). […]
-
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Assetmark Inc.
Assetmark Inc. trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 273,398 shares of the medical research company’s stock after selling 3,608 shares during the quarter. […]
-
Beta Wealth Group Inc. Boosts Holdings in Alphabet Inc. (NASDAQ:GOOG)
Beta Wealth Group Inc. grew its position in Alphabet Inc. (NASDAQ:GOOG – Free Report) by 44.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 20,075 shares of the information services provider’s stock after purchasing an additional 6,178 shares during the period. Alphabet accounts for about 1.5% of Beta Wealth Group Inc.’s portfolio, making […]